Delivering Your Clinical Study

At Aperio we understand the pressures that the biotechnology, pharmaceutical and medical device industries face.  It is critical that the projections, metrics and updates provided to your critical stakeholders – investors, board members and company leadership – are given with unwavering confidence in your CRO partner. Aperio earns this trust through our transparency, collaboration and proactive approach. Our combination of honest communication, quality standards and technology access give our sponsors the assurance that what we know, you know.

Quality is the essence of the Aperio DNA. Regardless of clinical study size, phase or services provided, we understand that quality deliverables are critical. Every project we touch goes through a detailed internal Quarterly Project Review to discuss project health with the clinical study and executive teams. Our Quarterly Quality Council addresses how Aperio measures up to our stringent corporate quality objectives. We have created a collaborative environment that empowers and holds all team members accountable to quality standards – in other words, no one passes the buck.

We will not compromise on quality...


Aperio’s DeliveryCommitments

  • 90% Monitoring Visit Reports Finalized On Time
  • 95% Monitoring Visit Window Compliance
  • 90% On-Time Delivery of Study Plans
  • 100% Training Compliance on Study Documents
  • 95% On-time Data Review
  • 85% Site Data Entry Currency
  • 95% CRA Retention